Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 9/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.41 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.40 |
| ▸ | MPI | P34949 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2486439 | 0.82 | TDP1 (0.58) | OPRL1OPRK1OPRM1OPRD1IP6K1 | |
| SCHEMBL30184152 | 0.80 | KDM4E (0.43) | OPRL1OPRK1OPRM1OPRD1IP6K1 | |
| SCHEMBL30184080 | 0.80 | KDM4E (0.43) | OPRL1OPRK1OPRM1OPRD1IP6K1 | |
| SCHEMBL23577945 | 0.80 | KDM4E (0.43) | OPRL1OPRK1OPRM1OPRD1IP6K1 | |
| SCHEMBL23590783 | 0.80 | KDM4E (0.43) | OPRL1OPRK1OPRM1OPRD1IP6K1 | |
| SCHEMBL2488961 | 0.79 | OPRL1 (0.48) | OPRL1OPRK1OPRM1OPRD1IP6K1 | |
| SCHEMBL23590784 | 0.79 | OPRL1 (0.38) | OPRL1OPRK1OPRM1OPRD1IP6K1 | |
| SCHEMBL4950174 | 0.78 | MPI (0.45) | MPITDP1POLB | |
| SCHEMBL23577793 | 0.75 | KDM4E (0.41) | OPRL1OPRK1OPRM1OPRD1IP6K1 | |
| SCHEMBL14310669 | 0.74 | OPRK1 (0.62) | OPRL1OPRK1OPRM1OPRD1IP6K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756112-B1 | PYRROLOBENZIMIDAZOLONES AND THEIR USE AS ANTIPROLIFERATIVE AGENTS | BOEHRINGER INGELHEIM INT (DE) | 2011-10-26 | — | — | EP | disclosed |
| US-7714010-B2 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20050261350-A1 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261350-A1 | Pyrrolobenzimidazolones and their use as anti-proliferative agents | MKI67, CCNI, CCNA1 | OPRL1 3406/4885OPRK1 2110/4885OPRM1 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.